CYPHERPUNK TECHNOLOGIES INC. Operating Lease, Expense
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Operating Lease, Expense of $113.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-13
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for the quarter ending 2023-09-30 was $113.00K, a 2.59% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for the quarter ending 2023-06-30 was $114.00K, a 1.79% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for the quarter ending 2023-03-31 was $114.00K, a 5.56% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for the quarter ending 2022-12-31 was $115.00K, a 6.48% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for fiscal 2022 was $451.00K, a 6.62% increase from fiscal 2021.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for fiscal 2021 was $423.00K, a 22.95% decline from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. operating lease, expense for fiscal 2020 was $549.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $113.00K 10-Q · filed 2023-11-13 | $227.00K derived: sum of 2 quarters · filed 2023-11-13 | $341.00K 10-Q · filed 2023-11-13 | $456.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $114.00K 10-Q · filed 2023-08-14 | $228.00K 10-Q · filed 2023-08-14 | $343.00K derived: sum of 3 quarters · filed 2023-08-14 | $459.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $114.00K 10-Q · filed 2023-05-15 | $229.00K derived: sum of 2 quarters · filed 2023-05-15 | $345.00K derived: sum of 3 quarters · filed 2023-11-13 | $457.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $231.00K derived: sum of 2 quarters · filed 2023-11-13 | $343.00K derived: sum of 3 quarters · filed 2023-11-13 | $451.00K 10-K · filed 2023-03-24 |
| 2022-09-30 | $116.00K 10-Q · filed 2023-11-13 | $228.00K derived: sum of 2 quarters · filed 2023-11-13 | $336.00K 10-Q · filed 2023-11-13 | $444.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $112.00K 10-Q · filed 2023-08-14 | $220.00K 10-Q · filed 2023-08-14 | $328.00K derived: sum of 3 quarters · filed 2023-08-14 | $433.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $108.00K 10-Q · filed 2023-05-15 | $216.00K derived: sum of 2 quarters · filed 2023-05-15 | $321.00K derived: sum of 3 quarters · filed 2023-05-15 | $426.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $213.00K derived: sum of 2 quarters · filed 2023-03-24 | $318.00K derived: sum of 3 quarters · filed 2023-03-24 | $423.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $105.00K 10-Q · filed 2022-11-14 | $210.00K derived: sum of 2 quarters · filed 2022-11-14 | $315.00K 10-Q · filed 2022-11-14 | $419.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $105.00K 10-Q · filed 2022-08-12 | $210.00K 10-Q · filed 2022-08-12 | $314.00K derived: sum of 3 quarters · filed 2022-08-12 | $419.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $105.00K 10-Q · filed 2022-05-13 | $209.00K derived: sum of 2 quarters · filed 2022-05-13 | $314.00K derived: sum of 3 quarters · filed 2022-05-13 | $456.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $209.00K derived: sum of 2 quarters · filed 2022-03-11 | $351.00K derived: sum of 3 quarters · filed 2022-03-11 | $549.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $105.00K 10-Q · filed 2020-11-12 | $247.00K derived: sum of 2 quarters · filed 2020-11-12 | $445.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $142.00K 10-Q · filed 2020-08-13 | $340.00K 10-Q · filed 2020-08-13 | ||
| 2019-09-30 | $211.00K 10-Q · filed 2020-11-12 | $420.00K derived: sum of 2 quarters · filed 2020-11-12 | $629.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $209.00K 10-Q · filed 2020-08-13 | $418.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |